Exclusive license agreement includes rights to develop and commercialize Cedilla’s CyclinE1/CDK2 inhibitors / Assets are currently in pre-clinical development with potential to serve patients with ...
Leverkusen, October 14, 2026 – In 2026, Bayer Foundation honors five outstanding scientists whose research opens up new perspectives and areas for action in health, agriculture and biomedical ...
The newest LifeHub in the Bayer network will connect the company more closely to the German innovation ecosystem of scientists, researchers, decision makers, and entrepreneurs / Focus lies on dialogue ...
Company plans to build state-of-the-art site in New Albany, Ohio, U.S., to serve patients in the U.S. as well as globally / Bayer expects to create around 600 new high-value jobs in the area / ...
Monheim, Germany/St. Louis, USA, September 9, 2026 – Bayer and Neste, the world’s leading producer of renewable diesel and sustainable aviation fuel, have finalized a commercial agreement to jointly ...
Science Based Targets initiative confirms target of a 42 percent reduction in Scope 1 and Scope 2 emissions by 2029 / 90 percent reduction in Scope 1, 2 and 3 emissions by 2050 / Bayer receives “A” ...
Not intended for U.S. and UK MediaChina’s Center of Drug Evaluation grants Priority Review designation for asundexian Priority Review designation is granted by the China’s Center of Drug Evaluation ...
The investment supports Bayer’s sustainability goal to help provide 100 million women in low- and middle-income countries with access to modern contraception by 2030 / The company’s facility in Turku ...
Bayer is committed to Ukraine. We have provided agriculture and healthcare products since 1992 and have more than 700 colleagues in the country. From the outset of Russia’s invasion of Ukraine, we ...
Effective April 15, 2025, he will succeed Dr. Robert Reiter who has decided to retire after 27 years with the company and 34 years in the industry / Dr. Mike Graham has profound expertise in R&D and ...
Further expansion of Bayer’s drug development pipeline in Women’s Healthcare / Innovative non-hormonal oral compound NT-814 to alleviate menopausal symptoms / Development compound recently completed ...
Bayer is committed to fostering diversity within both its workforce and supplier base. Through our “Responsible Procurement” program, we aim to support economic inclusion for underrepresented ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results